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ISPOR VISION: ISPOR is the leading global scientific and educational organization for health 
economics and outcomes research and their use in decision making to improve health.  
 
ISPOR MISSION: to promote health economics and outcomes research excellence to improve decision 
making for health globally. 
 
 
ABSTRACT 1 
 2 
As the leading health economics and outcomes research (HEOR) professional society, ISPOR 3 
has a responsibility to establish a uniform, harmonized international code for ethical conduct.  4 
ISPOR has updated its 2008 Code of Ethics to reflect the current research environment.  This 5 
code addresses what is acceptable and unacceptable in research, from inception to the 6 
dissemination of its results.  7 
There are nine chapters: 1 ± Introduction; 2 ± Ethical Principles (respect, beneficence and 8 
justice) with reference to a non-exhaustive compilation of international, regional, and country-9 
specific guidelines and standards; 3 ± Scope;  4 - Research Design Considerations (primary 10 
and secondary data related issues, e.g., participant recruitment, population and research 11 
setting, sample size /site selection, incentive/honorarium, administration databases, 12 
registration of retrospective observational studies and modelling studies); 5 ± Data 13 
Considerations (privacy and data protection, combining, verification and transparency of 14 
research data, scientific misconduct, etc.); 6 ± Sponsorship and Relationships with Others 15 
(roles of researchers, sponsors, key opinion leaders and advisory board members, research 16 
participants and IRB/EC approval and responsibilities); 7 ± Patient Centricity and Patient 17 
Engagement (new addition, with explanation and guidance); 8 - Publication and 18 
Dissemination; and 9 - Conclusion and Limitations.  19 
In addition, the ISPOR Code of Ethics Task Force developed a 64-point summary that is 20 
woven through the first eight chapters.  The summary, in its entirety, follows the report (p.23).  21 
A glossary follows.  Additional material can be found in 10 detailed appendices that include: 22 
other relevant codes of ethics, HEOR data sources, data protection considerations, recruitment, 23 
safety and reporting, incentive and disclosure requirements, IRB/EC roles and research 24 
participant involvement.  These are in a separate attachment and/or can be accessed via this 25 
link to:  https://www.ispor.org/TaskForces/ISPOR-Code-of-Ethics.asp  26 
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PREAMBLE TO CODE OF ETHICS 2017 27 
 28 
,6325H[SHFWVLWVPHPEHUVWRDGKHUHWRWKHKLJKHVWHWKLFDOVWDQGDUGVEHFDXVH,6325¶VDFWLYLWLHVDQG29 
those of its members affect a number of constituencies. These include, but are not limited to: 30 
x Patients - who are ultimately going to experience the greatest impact of the research. 31 
x Health care professionals - who will be treating or not treating patients with therapies, 32 
medications and procedures made available or not made available due to healthcare research. 33 
x Decision-makers and Payers - who must decide what is covered so as to optimize 1) the health 34 
of patients and 2) resource utilization. This includes: 35 
o Government Groups - who require the results of healthcare research to set policy and 36 
prices. 37 
o Insurers - who base health care coverage and/or payment decisions on healthcare 38 
research. 39 
o Employers - where healthcare research affects their decisions on providing health 40 
benefits. 41 
o Administrators and Others, such as U.S. managed care personnel, - who need results 42 
that are both practical and useful. 43 
x Professional Outcomes Researchers 44 
x Pharmaceutical Manufacturers - whose products are often the subject or focus of healthcare 45 
research. 46 
x Colleagues - where relationships in conducting research and related activities are particularly 47 
critical. 48 
x Research employees ± who are concerned about how they are regarded, compensated and 49 
treated by the researchers for whom they work 50 
x Students - where respect and appropriate behavior by researcher / employers is important. They 51 
are the future of the profession. 52 
x Clients - for whom healthcare research is conducted and researcher relationships are 53 
maintained. 54 
Through behaviors and practices intended to ensure that healthcare research is designed, conducted, 55 
and reported in the most proper and ethical way possible, the Code is a means for the science of health 56 
economics and outcomes research to avoid or address credibility challenges based on methodology or 57 
bias concerns.  By accomplishing this, the various affected constituencies will be able to trust and 58 
benefit from research findings as much as possible. The Code also includes some general ethical 59 
considerations for the Society. 60 
$VSDUWRIPHPEHUVKLSPHPEHUVDJUHHWRFRPSOLDQFHZLWK,6325¶V&RGHRf Ethics when they join or 61 
renew. However, we recognize that members' own organizations may also have ethical codes that 62 
should be followed. We also recognize legal considerations may sometimes be important, for example, 63 
in relation to employment law. ISPOR may deny or revoke membership, participation in groups or 64 
meetings if a member is convicted of a felony or other act or moral turpitude, or upon suspension of a 65 
license in a medical or health profession. 66 
CHAPTER 1:  INTRODUCTION 67 
 68 
As the leading health economics and outcomes research (HEOR) professional society*, ISPOR has a 69 
responsibility to establish a uniform, harmonized international set of standards or guidelines for 70 
members to follow.  Since 1998, an ISPOR Code of Ethics (Code) has been publicized to HEOR 71 
                                                        
* Pharmacoeconomics is a sub-discipline of health economics.  The ISPOR Code of Ethics uses the broader term, health 
economics, combined with outcomes research to form health economics and outcomes research or HEOR, which has become 
predominant since ISPOR was founded more than 20 years ago. 
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practitioners. This latest 2107 edition reflects the changing environment in which ISPOR and its 72 
membership conduct research. 73 
 74 
Those practicing in the HEOR area KDYHDORQJKLVWRU\RIFLYLOGLVFRXUVHDQGRIGHYHORSLQJ³JRRG75 
SUDFWLFHV´DVVRFLDWHGZLth different research designs. Such discussions and the templates developed 76 
are ways to reduce the unwarranted variation in professional outputs.  Nonetheless, a code of ethics 77 
differs from a recommended good or best practice recommendation.  It is concerned with principles, 78 
such as informed consent, data privacy and equity in healthcare.  79 
The core principles embodied in a code of ethics represent values that, on one hand, must not be 80 
compromised but, on the other hand, may need to be weighed against one another.  They are the 81 
guiding standards that are essential for the professionalism of researchers, and the confidence that 82 
users and members of other professions can have in HEOR.    83 
 84 
The composition of ISPOR as an organization is an important preface to what is to follow.  The global 85 
nature of ISPOR sets it apart from many other organizations, with differences in cultures and 86 
sometimes, points of view on important issues, such as data privacy.  ISPOR members represent 87 
multiple disciplines that approach intellectual problems in HEOR with a variety of tools and research 88 
designs.  They differ in the relationships that they have with different healthcare systems around the 89 
globe.  They come from diverse employment settings with complex and dynamic structures.   90 
As a multidisciplinary, global organization, ISPOR strives for representativeness, transparency, and 91 
balance in its activities, thereby, avoiding the appearance of bias or conflict of interest.  This includes, 92 
but is not limited to, sponsorship of its conferences and other activities, as well as presenters at its 93 
conferences.  To the extent that it is feasible, ISPOR program planning and selection committees should 94 
have a membership representative from all of its major constituencies. ISPOR should also have a Board 95 
of Directors that is representative of the various constituencies the Society serves. 96 
Furthermore, because significant research funding will come from funders with interests in specific 97 
findings (at times commercial, private non-profit, as well as governmental institutions, all have hoped-for 98 
outcomes), ISPOR should continue to maintain its own statement of objectivity and autonomy. ISPOR 99 
strives to assure that its journal, Value in Health, only publishes papers that have gone through a 100 
rigorous peer-review process, and whose authors are listed pursuant to strict criteria. 101 
 102 
(YHQWKRXJKHFRQRPLFVLVDPDMRUSDUWRI,6325¶VLGHQWLW\SULFHand coverage discussions, and similar 103 
topics, VKRXOGQRWEHFRQVWUXHGDVHQFRPSDVVLQJ,6325¶VWRWDOLGHQWLW\5DWKHU, ISPOR is conscious 104 
of broader ethical issues impacting global and regional medical resource allocation, public health 105 
policies and the global healthcare environment, and, on the research side, topics such as patient 106 
autonomy, patient outcomes and research conduct.  These issues include, but are not limited to: 107 
prejudice, equity in healthcare delivery, and access.   108 
 109 
The HEOR profession and research landscape have changed dramatically since the publication of the 110 
current Code in 20081 (Appendix 1) with the increased collection and use of real world data, rise of 111 
health information technology (IT), genomic information, focus on patient centricity, social media, and 112 
privacy issues, among others. Furthermore, most professional codes that ISPOR referenced in the past 113 
have been updated since last publication.  )LQDOO\GXHWRWKH6RFLHW\¶VLPPHQVHJURZWKLQERWK114 
membership and geographic coverage, it is important to recognize that there may be conflicting 115 
standards of professional conduct in regions of the world that now need to be considered LQ,6325¶V116 
Code (version 4).    117 
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 118 
Rather than merely reducing unwarranted variance, a code of ethics is intended to promulgate the 119 
standards that define what is acceptable and unacceptable in the conduct of all aspects of research, 120 
from its inception to the dissemination of its results.  This revised Code represents a collective effort to 121 
articulate those standards. 122 
Therefore: 123 
- ISPOR should publicize this Code of Ethics to members and non-members involved in 124 
pharmacoeconomics and outcomes research. 125 
- ISPOR should strive for a balance in sponsorship of its conferences and other activities by providing 126 
criteria for accepting of funding and ensuring full transparency, thereby avoiding the appearance of bias 127 
or conflict of interest. 128 
- Because, as a practical matter, most funding will come from different entities, ISPOR should continue 129 
to maintain its own statement of objectivity and autonomy. 130 
- ISPOR should strive to assure that its journal, Value in Health, only publishes papers that have gone 131 
through a rigorous peer-review process. 132 
- ISPOR should have a Board of Directors that is representative of the various constituencies the 133 
Society serves. 134 
 - The ISPOR program planning and selection committees should have membership representative of all 135 
of its major constituencies. 136 
- Like other professional societies, ISPOR should be conscious of broader ethical issues impacting 137 
global and regional medical resource allocation, public health policies and the global healthcare 138 
environment, and research topics such as patient autonomy and research conduct. These issues 139 
include, but are not limited to: prejudice, equity in healthcare delivery, and access.  140 
CHAPTER 2:  APPLICATION OF ETHICAL PRINCIPLES TO THE ISPOR CODE     141 
 142 
Both the past and the current Code of Ethics draw from international standards and guidelines. A non-143 
exhaustive compilation of international, regional, and country-specific guidelines and standards in the 144 
research field including patient engagement resources and publication ethics codes was reviewed and 145 
summarized (Appendix 2).  This range of standards includes, but is not limited to, the Belmont Report, 146 
the International Conference on Harmonization Good Clinical Practice (ICH GCP), the Agency for 147 
Healthcare Research and Quality (AHRQ) of the United States, the European Federation of 148 
Pharmaceutical Industries and Associations (EFPIA), Guidelines for Research Ethics in Japan, and the 149 
Genetic Alliance for patient engagement.  150 
 151 
Therefore: 152 
 153 
- Members should maintain a current knowledge of research practices, with due consideration of those 154 
practices most relevant to the research that is being done in their own countries. 155 
 156 
The ISPOR Code closely follows the Belmont Report¶Vthree fundamental ethical principles that form the 157 
EDVLVIRUWKH1DWLRQDO&RPPLVVLRQ¶VWRSLF-specific reports and the regulations that incorporate its 158 
recommendations.  Application of these principles requires careful consideration of informed and 159 
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voluntary consent, risks and benefits, and the selection of participants for research. 160 
 161 
Respect for persons: protecting the autonomy of all people; treating them with courtesy and 162 
respect; and allowing for informed and voluntary consent. Researchers must be truthful and 163 
conduct no deception; 164 
 165 
Beneficence: the philosophy of "Do no harm" while maximizing benefits for the research project 166 
and minimizing risks to the research participants; and 167 
 168 
Justice: ensuring reasonable, non-exploitative, and well-considered procedures are 169 
administered fairly ² the fair distribution of costs and benefits to potential research participants 170 
² and equally.   171 
 172 
,6325¶V&RGHSODFHVDGGLWLRQDOHPSKDVLVon privacy, transparency and civility. This reflects the 173 
responsibilities associated with increased data access, the global nature of research, and a broad range 174 
of research participants and health care system stakeholders. 175 
 176 
Therefore: 177 
 178 
- Privacy: Members who work in HEOR can be privy to data sources containing protected health 179 
information (PHI) and other personal data from patients.  It is essential that these data are handled with 180 
utmost care so that patient confidentiality be maintained at all times and no breaches to patient privacy 181 
occur.  182 
- Transparency and Integrity: Members must disclose research methods in sufficient detail to permit 183 
replication. The funding sources should be clearly acknowledged, and any conflicts of interests declared.  184 
Designing, conducting and especially reporting of the study should be an unbiased reflection of the full 185 
range of findings generated.  186 
- Civility: Members¶ research and discussion should respect the dignity of all participants. Respecting the 187 
dignity of patients and providers of care is clearly a responsibility.  It is also a responsibility to treat fellow 188 
researchers with respect.   189 
All HEOR studies should respect and protect the human subjects enrolled in those studies, using the 190 
principles of the Declaration of Helsinki (1964-2013).2 Medical research is subject to ethical standards 191 
that promote and ensure respect for all human subjects and protect their health and rights. While the 192 
primary purpose of medical research is to generate new knowledge, this goal can never take 193 
precedence over the rights and interests of individual research participants. 194 
CHAPTER 3:  SCOPE OF THE CODE  195 
 196 
The ISPOR Code of Ethics is specifically oriented to HEOR.  While there is overlap with other fields, our 197 
goal is a discipline-oriented Code. It is important to note that the scope of this Code of Ethics does not 198 
include ethical considerations related to the use or impact of specific HEOR measures, e.g., potential 199 
age-related biases implicit in quality-adjusted life years.  200 
 201 
,6325¶V&RGHRI(WKLFVFRYHUV the conduct of HEOR, but not societal decision making based on HEOR 202 
evidence, such as formation of HTA policies.  As long as reporting of research is complete and 203 
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transparent, users RI,6325PHPEHUV¶UHVHDUFKFDQMXGJHXVHRULPSDFWLVVXHVLQGHSHQGHQWO\  For 204 
more on these issues, please refer to the Second Panel on Cost Effectiveness in Health and Medicine.3  205 
 206 
Health economics is a branch of economics, a discipline that analyzes the economic aspects of all 207 
activities designed to improve or maintain health and health care, typically focusing on the costs (inputs) 208 
and the consequences (outcomes) of health care interventions.  It is concerned with issues related to 209 
efficiency, effectiveness, utility, value, quality, ethics and behavior in the production and consumption of 210 
health and health care. In broad terms, health economists study the functionality of health care systems 211 
and health-affecting behaviors.4 212 
 213 
Outcomes research is the scientific discipline that evaluates the effect of health care interventions on 214 
patient well-being, including clinical, economic and patient-centered outcomes. (ISPOR Book of Terms)   215 
 216 
Difference and relationship to other research fields 217 
HEOR is closely related to other common research types, such as clinical trial/studies, non-218 
interventional observations, epidemiologic investigations, real world research and market research 219 
studies (See Appendix 3 for more information).  220 
 221 
There is no single legal instrument or practical guidance for HEOR.  At times, this results in differences 222 
in definitions and terms across groups and countries.  HEOR can utilize any techniques from the 223 
research types mentioned above. The objective is to evaluate the effect of health care interventions on 224 
patient well-being, including clinical, economic, and patient-centered, and other relevant outcomes, as 225 
well as the functioning of health care systems and health-affecting behaviors.  226 
 227 
Therefore: 228 
 229 
- Members should adhere to the standards of practice for their respective fields of research and identify 230 
any official guidelines and standards used. 231 
 232 
This 2017 Code of Ethics covers the following five topics in depth: research design, data 233 
considerations, sponsorship, patient engagement, and publication and dissemination with appendices 234 
providing ancillary detail to these sections. 235 
CHAPTER 4:  RESEARCH DESIGN CONSIDERATIONS 236 
 237 
HEOR comprises a range of research designs from modeling and retrospective analyses using 238 
secondary data to prospective observational and clinical trial designs (See Appendix 4 for more on 239 
HEOR data sources).  No matter the chosen research design, HEOR is conducted following the core 240 
scientific principles of objectivity, transparency, reporting, and quality assurance. It is defined by the 241 
objective(s) and the approach, not by the title of the work or the role of those commissioning the work. 242 
 243 
Primary Data-Related Research Considerations 244 
 245 
Participant Recruitment 246 
ISPOR recognizes that study participants can be recruited via a number of methods.  247 
 248 
Therefore,  249 
 250 
ISPOR Code of Ethics 2017 
Final Draft for Review Only 
 
 
7 
 
From the point of ³first contact´ researchers should provide potential subjects information about study 251 
intentions and how the research is funded, as well as all information mandated in their proposals as 252 
reviewed by institutional review boards (IRBs)/research ethics committees (RECs). (See Appendix 5 for 253 
more details.) 254 
 255 
Population and Research Setting 256 
Researchers should be specific with regard to population and setting.   257 
 258 
Therefore,  259 
 260 
Members should describe the analytic study population in terms of persons, geography, time period, and 261 
selection criteria.  Members should choose, and obtain permissions to use, a suitable research setting 262 
and/or existing data or literature to provide information about a specific population to which the study 263 
results are meant to apply.  264 
 265 
Sample Size, Site Selection  266 
Study sample size should not be larger than statistically necessarily. Inadequate sample size (too low) 267 
may provide insufficient data to answer the intended research questions or will provide low precision5.  268 
 269 
Therefore, 270 
 271 
The number of patients and sites selected for a study should be appropriate to meet the research 272 
objectives.  273 
 274 
Safety / (Serious) Adverse Events 275 
Safety and adverse event reporting (AER) is an important aspect of all primary research involving 276 
patients and medical interventions. The Guideline on good pharmacovigilance practices (GVP)6 laid 277 
down in WKH(XURSHDQ8QLRQ¶VDirective 2010/84/EU7 applies to investigational medicinal products and 278 
non-investigational medicinal products.  Similar regulations exist in most other jurisdictions. AER is 279 
applicable to some HEOR activities, including clinical trials, primary research, non-interventional 280 
studies, market research, and real world research. (For more information, see Appendix 6.) 281 
 282 
Researchers are expected to collect and report adverse events, not only due to regulatory and legal 283 
requirements, but also with an understanding of the responsibility to patients and society to 284 
comprehensively inform the safety of treatment options.  285 
 286 
A strong international collaborative approach to post-approval surveillance and mandatory adverse 287 
reporting is critical. Data collected through social and digital media can be useful, but often do not follow 288 
clear pharmacovigilance reporting guidelines because there is no single marketing authorization holder.  289 
 290 
Therefore: 291 
 292 
- The balance of risk or harm to benefit for patients must be considered in HEOR studies, and must be 293 
communicated to patients via informed consent. 294 
-Safety and adverse event reporting (AER) are important aspects of all primary research involving 295 
patients and medical interventions, are applicable to many HEOR activities, and must follow 296 
international guidelines. 297 
 298 
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Incentive/Honorarium 299 
$QµLQFHQWLYH¶RUKRQRUDULXPLVDQ\EHQHILWJLYHQWRDSDUWLcipant to encourage participation in a 300 
research study. It is commonly used in prospective research and surveys to provide participants with 301 
compensation for expenses that may be incurred as part of participating in research. Remuneration is 302 
compensation to investigators or consultants for their work or contribution to the study.   For specific 303 
details on incentives and honoraria, see Appendix 7. 304 
 305 
Therefore,  306 
 307 
Any such proposed payments are, of course, subject to receivers and SURYLGHUV¶LQWHUQDOFRPSOLDQFH308 
guideline and IRB/EC approval, and must be detailed in the research proposal submitted for review.  309 
 310 
Researchers need to be diligent in ensuring that the incentive would not induce research participants to 311 
accept risks they would not be willing to accept if they were offered a smaller or no incentive.  312 
 313 
 314 
Secondary Data-Related Research Considerations:  315 
 316 
Administrative Databases and Other Large Datasets  317 
Health care systems generate operational and administrative data that have been used extensively in 318 
HEOR studies.  HEOR uses a wide range of secondary research sources, including proprietary 319 
databases, claims databases, patient registries, routine data sources, systematic reviews, evidence 320 
synthesis, social media, Internet of Things (IoT), and other related sources. Data can range from a 321 
longitudinal administrative database to a constant flow from IoT and wearable devices, or from 322 
controlled clinical trials to unstructured social media feeds.  323 
 324 
Examples include governmental databases like the 86¶VCenter for Medicare and Medicaid Services 325 
(CMS), Chronic Condition Data Warehouse (CCW), SEER Medicare8, the United KLQJGRP¶V HES9, 326 
)UDQFH¶VSNIIRAM10 etc., as well as a number of private databases.  Some research involves 327 
combining various datasets (e.g. Medicare Current Beneficiary Survey and Medicare Claims Parts A, B, 328 
C or D).   This diversity in types of datasets presents multiple analytic challenges. 329 
 330 
Because the data were initially collected for another purpose, the key first step for those creating and 331 
then using secondary data is to be sure that all intellectual property rights have been respected and that 332 
the appropriate permissions have been secured.  This is typically done by the database supplier.  These 333 
permissions include protection of the privacy of the individuals whose characteristics are captured in the 334 
database, as well as their informed consent for secondary use of their data, where applicable.  Privacy is 335 
discussed below.   336 
 337 
The cost of creating databases for secondary use is sometimes borne by governments and the users are 338 
charged nominal fees.  When private entities build databases for secondary use they will often do so in 339 
anticipation of higher user fees that make database creation and distribution a worthwhile commercial 340 
endeavor.  In either case, the researcher needs to be assured that the database was legally and 341 
ethically constructed. 342 
 343 
The vast majority of HEOR studies currently conducted involve the analysis of secondary data. 344 
Retrospective observational studies are often conducted using administrative databases or clinical 345 
registries. Modeling studies involve the synthesis and analysis of data from several sources, including 346 
previously conducted clinical trials, clinical registries, routinely available cost data, and the published 347 
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literature. The use of secondary data has ethical challenges related to the collection and storage of 348 
personal data that are different from those in primary research studies (discussed above), since the data 349 
are already anonymized. If there is doubt or moral concern regarding how the secondary data were 350 
generated, researchers can consider a due diligence process on the data source before using it, or can 351 
use an alternative dataset for the study.    352 
 353 
There are instances where a secondary database may not be considered de-identified.  One example is 354 
the CMS Chronic Condition Warehouse where age and postal zip code information are included.   355 
However, given the large degree of analyst discretion, secondary research studies do raise a number of 356 
ethical challenges relating to the avoidance of methodological bias due to the selective use of the 357 
available data and the inappropriate use of assumptions regarding such things as missing data, the 358 
nature of selection bias, outliers, and so on. Therefore, the most important general ethical principles in 359 
the analysis of secondary data are those of µWUDQVSDUHQF\DQGUHDVRQDEOHQHVV, i.e., in the absence of 360 
consensus on principles, a fair process allows us to agree on what is legitimate and fair.¶11 361 
 362 
Therefore,  363 
 364 
- When using secondary data sources initially collected for another purpose, HEOR researchers 365 
should ensure that intellectual property rights are respected and that all the appropriate 366 
permissions have been secured. 367 
 368 
- Given the potential for bias in the analysis of secondary data, the most important general ethical 369 
SULQFLSOHVDUHWKRVHRIµUHDVRQDEOHQHVV¶DQGµWUDQVSDUHQF\¶ 370 
 371 
 372 
Registration of Retrospective Observational Studies  373 
For purposes of this Code, observational studies are defined as analysis of existing datasets.1213  While 374 
the registration of research is more common for clinical trials than for observational studies, Williams et 375 
DODUJXHWKDWµ0XFKRIWKHUDWLRQDOHIRUWKHSURVSHFWLYHUHJLVWUDWLRQRIFOLQLFDOWULDOVDSSOLHVWRWKH376 
registration of observational studies¶.14  These obligations include oversight by ethical review boards, 377 
informed consent, and public release of the study findings to advance biomedical knowledge. As with 378 
clinical trials, incomplete reporting of observational studies has been documented. Some researchers 379 
suggest that observational studies are also at increased risk for publication bias or other types of bias, 380 
including misrepresentation of pre-specified analyses or disease classification coding. Such biases are a 381 
concern because they undermine the validity of observational studies, which are an important 382 
component of the medical evidence base in areas of public health, such as detection of rare adverse 383 
events. 384 
 385 
Therefore,  386 
 387 
- In those instances in which study methods include analysis of a database, members should describe 388 
approaches, methods, technologies used to ensure data completeness and validity as well as the 389 
software package(s) used for data analysis. Members should have the education, training and 390 
experience to perform the assigned tasks.  391 
 392 
- While registration of observational studies is generally not required at this time, members are 393 
encouraged to register such studies prospectively to recognize ethical obligations to patients and to 394 
avoid the potential for publication bias. 395 
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 396 
- Where a HEOR study is being conducted alongside a clinical study gathering data prospectively (such 397 
as a clinical trial or observational study), where possible members should ensure that the clinical study 398 
concerned has been registered on ClinicalTrials.gov, Patient Registries (e.g. patientregistry.ahrq.gov), 399 
EU electronic Register of Post-Authorisation Studies (EU PAS Register)15, or equivalent database in 400 
their own country. 401 
 402 
ISPOR has published a number of Good Practices for Outcomes Research Reports16 on conducting 403 
outcomes research (clinical, economic or patient-reported) or using outcomes research in health care 404 
decisions.  While these reports do not address ethical principles directly, the specification of good 405 
research methods is an important component of recognizing and eliminating analytic bias. 406 
 407 
Modeling Studies 408 
 409 
In these HEOR studies, secondary data from multiple sources are synthesized using a decision-analytic 410 
model. Although this is the main application of modeling, models are sometimes used to extrapolate 411 
costs and benefits beyond the end of a clinical trial in a primary research study. The ethical principles 412 
discussed here apply equally to both situations. 413 
 414 
The general ethical principles of reasonableness and transparency suggest a number of approaches for 415 
the conduct of modeling studies.  ISPOR with the Society for Medical Decision Making published seven 416 
Modeling Good Research Practices Task Force Reports17.  The seventh, on model transparency and 417 
validation18, is the most relevant task force report to the ISPOR Code of Ethics. 418 
 419 
Therefore,   420 
 421 
In conducting modeling studies, members should ensure that the input parameters are estimated based 422 
on a comprehensive review of the available literature. For the key parameters of the model (e.g., the 423 
estimate of relative treatment effect) it may be necessary to conduct a full systematic review and meta-424 
analysis.  425 
 426 
However, decision-analytic models typically rely on numerous parameter estimates and it will not be 427 
possible to undertake a full systematic review for each. Therefore, members should be transparent about 428 
the estimates they use for key parameters, provide the logic they used in selecting particular estimates 429 
and explore the impact of their choices through sensitivity analysis. (Sensitivity analysis is widely used in 430 
economic evaluation and explores the sensitivity of the study results to the variation in the input 431 
parameters.) 432 
 433 
Another important feature of modeling studies is the need to make assumptions, either about the 434 
parameter estimates in situations where data are absent or inadequate parameter uncertainty19, or about 435 
model structure (structural uncertainty). The ethical principles of reasonableness and transparency 436 
would dictate that any assumptions are clearly explained and justified. In addition, sensitivity analyses 437 
should be conducted to explore the importance (in terms of the overall estimate of cost-effectiveness) of 438 
the assumptions made. 439 
 440 
Reporting is discussed further in Chapter 8: Publication and Dissemination. 441 
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CHAPTER 5:  DATA CONSIDERATIONS 442 
 443 
This section provides guidance on data considerations in privacy, data protection, combining research 444 
data, data validity20, transparency, and scientific misconduct. Members should ensure selection of 445 
suitable data sources and adequate sample size to power the question(s) being studied. 446 
 447 
Privacy and Data Protection 448 
Protecting participants¶ privacy is paramount to all forms of clinical research, including HEOR. 449 
Regulations such as the EU GDPR21 U.S. HIPAA22), Japan APPI23 cover the collection of data relating to 450 
an identifiable person. For data protection purposes, original holders of personal data can, if 451 
contractually bound, transfer personal data to other parties without seeking additional explicit 452 
permission of the data subject, as long as the data are being used for a purpose for which the original 453 
holder has a lawful basis to process the personal data, including the consent of the data subject. This 454 
would need to be an integral part of the informed consent process and would require IRB approval.  455 
Details of data processing, security, storing, transfer, and SDUWLFLSDQWV¶ULJKWVWRWKHLUSHUVRQDOGDWDDUH456 
detailed in Appendix 8.  457 
 458 
Combining Research Data  459 
It is sometimes possible to enrich an existing database by linking additional information that is relevant 460 
to the individual patient or the provider.  Examples include linking socioeconomic information about the 461 
neighborhood surrouQGLQJWKHSDWLHQW¶VKRPHRUWKHWUDLQLQJKLVWRU\RIWKHVSHFLILFSURYLGHUGHOLYHULQJD462 
service.  The most effective linkages take full advantage of the identifying characteristics of the patient 463 
or the provider.  Adding data to an existing database can lead to the subtle erosion of privacy 464 
protections.  As a result, some database providers insist on limiting potential links. It is critical to protect 465 
the commitment to privacy during and after the linkage of additional data.  Combining of research data 466 
must also have been approved by the IRB. 467 
 468 
Data Verification  469 
On occasion, access to these data may be requested by journal reviewers or other researchers wishing 470 
to verify the analyses used in the research. It is important that researchers, sponsors and the owners of 471 
data recognize that the credibility of the research is lessened if other parties cannot adequately verify it.  472 
 473 
This is particularly important if one of the objectives of the research is to inform health care decision 474 
makers, who in turn may have to justify the basis on which they made a particular decision. This 475 
suggests that the maximum level of access, within the law, should be granted by researchers to 476 
anonymized, group-level data and that the contracts for undertaking the research should reflect this 477 
consideration. 478 
 479 
Therefore: 480 
 481 
- When a database (from primary data collection and/or secondary data use) is analyzed, members 482 
should provide a description of approaches, tools, and technologies used to store the data and maintain 483 
patient privacy/confidentiality and de-identification. 484 
 485 
- Personal data should be maintained securely and adequate back-up should be maintained. Data 486 
access should be limited to authorized individuals. Control systems should be put in place to ensure 487 
authenticity, integrity, and confidentiality of data records when transmitted electronically. 488 
 489 
- Researchers should offer the maximum level of access to the anonymized, group-level data used in 490 
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their research.  If data access is restricted by proprietary or contractual considerations, those 491 
considerations should be disclosed. If journal reviewers deem it important that statistical review of 492 
proprietary data be conducted, authors should work with both the data owners and the reviewers to find 493 
appropriate confidential arrangements for such review whenever feasible. 494 
 495 
Transparency of Research and Data 496 
 497 
Transparency and replicability are crucial to HEOR. Transparency of data and replicability of results are 498 
important issues that pose challenges for authors, reviewers and journals (Cochrane 2015)24.  Some 499 
MRXUQDOVKDYHH[SOLFLWGDWDSROLFLHV,6325¶VMRXUQDOValue in Health has its own, and ISPOR members 500 
± as well as all contributors ± are expected to comply with this policy25.  501 
 502 
Nevertheless, it is recognized that for many, if not most reviewers, detailed review of data, programs, 503 
and results is not feasible in the context of performing a timely manuscript review.  For those who are 504 
able to do so, such review is encouraged (see Cochrane 2015). Those who are not able to do so, but 505 
have reason to believe that data review is indicated, should inquire with the editor about the possibility 506 
of employing an independent statistical reviewer.  507 
 508 
Therefore: 509 
 510 
- 0HPEHUV¶K\SRWKHVHVDQGUHVHDUFKGHVLJQVVKRXOGEHGHILQHGDSULRULUHSRUWHGWUDQVSDUHQWO\511 
defended relative to alternatives, and planned to recognize and minimize all types of bias. 512 
 513 
- Members should fully disclose the identity of sponsors of their research. 514 
 515 
- Members should strive to avoid bias and the appearance of bias in conducting research, such as in the 516 
choice of methods and data inputs, or in the selective reporting of results 517 
 518 
- Members should be aware of conflicts of interest and the appearance of conflicts of interest. As a point 519 
of reference, members should look to the rules on disclosure of potential conflicts of interest laid down 520 
by major peer-reviewed journals and their own institutions. 521 
 522 
- Members should maintain their professional autonomy and objectivity in conducting and reporting, in 523 
writing or verbally, research findings. 524 
 525 
- Methods sections of papers should identify and justify all departures from the a priori analysis plan. 526 
 527 
For authors, posting of data and programs is good practice and strongly encouraged whenever 528 
feasible.  Best efforts should be made to make them at least available to reviewers when requested, 529 
under confidential arrangements, if necessary. When citing articles in a manuscript, known replicability 530 
RIWKRVHDUWLFOHV¶UHVXOWVVKRXOGEHDQLPSRUWDQWFRQVLGHUDWLRQ.  This is particularly true for those that 531 
DUHLQIOXHQWLDOWRWKHPDQXVFULSW¶VDSSURDFKRUFRQFOXVLRQV 532 
 533 
Similarly, transparency of data and replicability of research results should be serious considerations for 534 
those organizing conferences, discussing papers, serving on awards or selection committees, writing 535 
promotion or tenure letters, hiring researchers, etc.  536 
 537 
Scientific Misconduct 538 
Scientific misconduct is the violation of standard codes of scholarly conduct and ethical behavior in 539 
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professional scientific research. According to the ICMJE26, it includes, but is not necessarily limited to: 540 
data fabrication, data falsification including deceptive manipulation of images, and plagiarism.  See also 541 
Chapter 8: Publication and Dissemination. 542 
 543 
The Committee on Publication Ethics (COPE) has developed procedures for editors to follow if there 544 
are concerns about the integrity or conduct of work in submitted or published papers or if scientific 545 
misconduct is suspected. The procedure emphasizes transparency and accountability throughout the 546 
investigation, as well as communication of the whole process. While some may consider failure to 547 
publish clinical trial results or other human studies a form of scientific misconduct, each situation of 548 
alleged misconduct requires individual assessment by relevant stakeholders.  549 
 550 
Therefore: 551 
 552 
- Members should maintain and protect the integrity of data used in their studies as well as on any 553 
other aspect of their research, as previously discussed (e.g., respect for patient autonomy such as 554 
informed consent and data privacy). 555 
 556 
- Members should not draw conclusions beyond or inconsistent with what their data would support and 557 
discuss any limitations in a transparent manner. 558 
CHAPTER 6:  SPONSORSHIP AND RELATIONSHIPS WITH OTHERS 559 
 560 
HEOR sponsors range from life sciences industry and health care insurers to provider and patient 561 
associations and governmental bodies. However, it is understood that much of the funding available to 562 
those who pursue HEOR is provided by bodies with vested interests. $FHQWUDOSULQFLSOHRI,6325¶VZRUN563 
is the maintenance of its own objectivity and autonomy from sponsors and commercial interests.   564 
 565 
Researchers  566 
Those who conduct HEOR should strive to make the nature, scope, and potential of their work clear to 567 
sponsors. This not only includes being transparent about the kind of knowledge scientific research can 568 
generate but also pertains to the ethical dimension of conducting research. Thus researchers should 569 
make it clear to sponsors that all outputs from a research project will include the acknowledgement of all 570 
sources of funding as part of a conflict of interest declaration.  571 
 572 
Furthermore, researchers should not only avoid being placed in a position where they experience a 573 
conflict of interest, they should also avoid the appearance of a conflict of interest, and the possibility that 574 
their research will be perceived as biased. 575 
 576 
When engaging with sponsors, researchers should be clear about the need to maintain their professional 577 
autonomy over all stages of the research, including its design, conduct, and publication. The autonomy 578 
of science contributes to the objectivity of research and, therefore, the authority of the researcher.  579 
 580 
Sponsors should be informed about the opportunities to enter studies into research registries, as well as 581 
their rights (or lack thereof) of access to - and ownership of - the data generated or collected as part of 582 
the research.  583 
 584 
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When researchers accept sponsorship for a particular project they should be in a position to conduct the 585 
research in a manner that is both timely and reflects the required level of scientific quality and 586 
methodological rigor.  587 
 588 
HEOR is conducted through close collaboration within teams and between teams, nationally and 589 
internationally. The principle of civility is important to ensure that the contribution from all parties is 590 
respected and understood. Employees and employers have responsibilities to ensure that reputations, 591 
rights, interests of all parties are respected, and that work is done to appropriate standards protecting 592 
proprietary information. Particular care should be taken to ensure that there is no perception of actual 593 
abuse of the relationship between more senior faculty members and students. 594 
 595 
Therefore: 596 
 597 
- Members should respect the reputations and rights of colleagues when engaged in collaborative 598 
projects. 599 
 600 
- Members should treat their research employees with respect and should compensate them fairly for 601 
their work. 602 
 603 
- Members should protect and promote the interests of their employers, provide competent work, 604 
adhering to these broader guidelines, and protect proprietary information. 605 
 606 
- Members should treat students with respect and refrain from exploiting them under any circumstances. 607 
 608 
Responsibility to Sponsors  609 
HEOR must not be used to obtain confidential information about competing products and companies 610 
from participants who are bound by confidentiality agreements with those companies. 611 
 612 
A researcher may transfer any or all of the UHVHDUFKHU¶Vresearch duties and functions to one or more 613 
subcontractors (e.g., CROs). All parties, including subcontractors, should be contractually bound by the 614 
same legal and ethical requirements as the main researcher. 615 
 616 
Therefore: 617 
 618 
- Members acting as sponsors should allow HEOR researchers at all times to maintain their scientific 619 
integrity and adhere to relevant standards in conducting and reporting research. 620 
 621 
- Members should respect contractual rights when they agree to perform work for hire and should refrain 622 
from disseminating information which they agreed in advance to keep proprietary. 623 
 624 
Key Opinion Leaders (KOLs) and Advisory Board Members  625 
The role of KOL brings some ISPOR members into close contact with sponsors. As such, we reiterate 626 
the centrality of independence, professional autonomy and objectivity to the scientific process, including 627 
dissemination of scientific findings.  628 
 629 
Therefore: 630 
 631 
ISPOR Code of Ethics 2017 
Final Draft for Review Only 
 
 
15 
 
- When acting as KOLs, ISPOR members should be transparent about payments ± and any other 632 
benefits - they receive for acting in this capacity.  633 
 634 
- When acting as KOLs, ISPOR members should ensure that the information they are presenting is an 635 
accurate representation of the facts available. They should respond to questions and queries honestly 636 
and to the best of their abilities.  637 
 638 
- When relying on KOLs, ISPOR members should critically engage with the claims being made. Where 639 
appropriate they should seek independent corroboration of any factual claims and consider the full range 640 
of alternatives for themselves.  641 
 642 
- When acting as Advisory Board Members, ISPOR members should maintain their independence and 643 
professional autonomy and act transparently, e.g., declare conflicts of interest.  644 
 645 
Responsibility to Research Participants  646 
Researchers should be open and transparent about the aim and objectives of their research, its design, 647 
its conduct and its potential consequences or outcomes. They should be clear with participants about 648 
what is being asked of them, the right to refuse to participate, and the possibilities of withdrawing at a 649 
later date.  650 
 651 
While it might not always be possible, realistic or particularly desirable, researchers should, where 652 
appropriate, aim to communicate results of research to participants. Responsibilities to communicate 653 
aggregated results to participants should be clearly stated in consent materials or processes. 654 
 655 
Informed consent is the tool to ensure that trial participants understand the context and specifics of 656 
clinical trials and/or health care-related research.  The informed consent document should be relevant, 657 
easily understandable and practical.  It should not serve as a theoretical exercise for the researcher.  A 658 
copy of the signed informed consent must be provided to the participant. 659 
 660 
Ethical review of research proposals should, where appropriate, seek input from individuals or 661 
organizations that are able to represent the perspective of patients.  662 
 663 
Therefore: 664 
 665 
- Members should respect the autonomy of research participants in designing and conducting studies, 666 
specifically, but not limited to, informed consent and data privacy. 667 
 668 
IRB/EC Approval 669 
Sponsors should ensure that IRB/EC approval is obtained, as appropriate for the planned research. It is 670 
the responsibility of an IRB/EC to ensure that the rights, safety and well-being of those involved in 671 
research are protected.  Furthermore, it should provide public assurance of that protection by, among 672 
other things, reviewing and approving / providing a favorable opinion on the research proposal, the 673 
suitability of the investigator, facilities, and the methods and material to be used in obtaining and 674 
documenting informed consent of research subjects.  675 
 676 
Requirements of the IRB/EC approval shall depend on the research type, study objectives, interaction 677 
with patients and competent authority requirement from different countries.  Some recommendations of 678 
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IRB/EC for different studies appear in Appendix 9. The legal status, composition, function, operations 679 
and regulatory requirements pertaining to independent ethics committees may differ among countries.  680 
 681 
Appendix 10 provides for involvement of different participants groups, including healthy volunteers, 682 
patients, protected classes, children and vulnerable populations. 683 
CHAPTER 7:  PATIENT CENTRICITY AND PATIENT ENGAGEMENT IN RESEARCH 684 
 685 
The ISPOR Code has been updated to appropriately reflect an increased focus on patient centricity and 686 
patient engagement in research by regulatory and health technology assessment (HTA) agencies, policy 687 
and decision makers, medical technology manufacturers, research organizations, payers and other 688 
VWDNHKROGHUVVHHNLQJWRXQGHUVWDQGSDWLHQWV¶SHUVSHFWLYHVDQGH[SHULHQFHV2UJDQL]DWLRQVVXSSRUW689 
patient centricity in research for a number of reasons from improved research, utility and efficiency of 690 
clinical trials to ethical concerns and societal and moral obligations.  Furthermore, the involvement of 691 
patients or their representatives increases transparency, mutual respect and trust between patients and 692 
other stakeholders, including payers and providers. 693 
 694 
Reflecting this evolution in the research environment, as an organization, ISPOR has moved to become 695 
more patient-FHQWHUHG,WDOLJQVZLWK,6325¶VPHPEHUV¶LQWHUHVWVDQG,6325¶VRYHUDOOPLVVLRQWR696 
promote health economics and outcomes research excellence to improve decision making for health 697 
globally.  In 2015, the ISPOR Board of Directors unanimously approved a motion to create a special 698 
category of membership within ISPOR for patient representatives to increase patient involvement 699 
WKURXJKRXW,6325¶s activities.  700 
 701 
Understanding Patient Centricity and Patient Engagement 702 
As of 2017, there is no standard definition of patient centricity or patient engagement. Significant 703 
variation exists in how different stakeholders and sectors (e.g., regulators, HTA agencies, the 704 
pharmaceutical industry, academia, hospitals, and patient organizations) define these terms.   705 
 706 
Patient-centric research should focus on the outcomes that are meaningful and important to patients, 707 
ZLWK³WKRVHRXWFRPHVLPSRUWDQWWRSDWLHQWV¶VXUYLYDOIXQFWLRQRUIHHOLQJVDVLGHQWLILHGRUDIILUPHGE\WKH708 
patients WKHPVHOYHVRUMXGJHGWREHLQSDWLHQWV¶EHVWLQWHUHVWVE\SURYLGHUVDQGFDUHJLYHUVZKHQ709 
SDWLHQWVFDQQRWUHSRUWIRUWKHPVHOYHV´27 In order to understand what is important to patients, they must 710 
be meaningfully engaged in the research from start to finish. Patient-centered outcomes may or may not 711 
be measured by patient self-report28.  712 
 713 
Operationalizing Patient Centricity and Patient Engagement 714 
 715 
Levels of Patient Engagement 716 
Patient engagement can take many forms.  Examples of little or minimal engagement include asking for 717 
patient input by gathering patient reactions and regarding patients as study subjects only.  It is low 718 
intensity engagement with unidirectional communication.   719 
 720 
More meaningful levels of engagement include collaboration and bi-directional communication. 721 
Examples include patient experts in an advisory role providing a priori consultation on study design, 722 
procedures and\or outcomes.  It is more active, higher-intensity involvement between researcher and 723 
consumer or patient representatives.  At the high end of the engagement spectrum is shared leadership 724 
and partnership, characterized by a priori, as well as continuous interaction.  At this level, patients have 725 
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a governance role and are paid investigators or consultants. At the highest level of engagement, the 726 
research is patient-driven. 727 
 728 
There are a number of useful frameworks for patient engagement29. They describe (1) patient 729 
involvement through interchange between the patient and provider; (2) the stages of research in which 730 
patients can be involved; and (3) prioritizing stakeholder engagement in research.  They serve as a 731 
conceptual basis for patient engagement in medical product development.  732 
 733 
Researchers should also consider the role of families and family caregivers when taking a patient-734 
centered approach.  Some patients will be unable to engage due to their age or condition. For some 735 
illnesses, there is a significant impact on family life and family caregivers. It is important to include family 736 
and caregiver engagement under these circumstances. 737 
 738 
Timing of Patient Engagement 739 
3DWLHQWLQSXWLVYDOXDEOHWKURXJKRXWWKHPHGLFDOWHFKQRORJ\¶VOLIHF\FOHfrom early development through 740 
dissemination and post-market surveillance.  Early and meaningful involvement of knowledgeable 741 
patient representatives and members of patient organizations in setting research questions is highly 742 
recommended.  Collaboration with patient organizations as part of the research team is also 743 
HQFRXUDJHG7RDFFXUDWHO\FDSWXUHSDWLHQWV¶YDOXHVDQGSUHIHUHQFHVSDWLHQWVVKRXOGEHLQYROYHGLQ744 
benefit/risk evaluation and related activities throughout the development lifecycle.  A planned sequential 745 
approach is recommended where feedback from patients is collected and considered30.     746 
 747 
The patient perspective is especially critical in early phases to determine unmet needs and the correct 748 
study endpoint(s) for medical label claims.31 Patient input at the study design stage can improve site 749 
selection and recruitment, (e.g. within indigenous or other historically disadvantaged populations), data 750 
collection, and reduce patient burden. Patients (or patient organizations), should actively contribute to 751 
trial documents directed at patients to ensure that the content and format are understood.  752 
 753 
Patients and patient organizations can also help in the translation of research results by helping to 754 
develop and share lay-person-level summaries of clinical trial results. Finally, patient input is also 755 
needed in assessing real-world effectiveness, cost effectiveness, and value. These assessments should 756 
be enriched with patient input and guided by patient experiences32.    757 
 758 
Partnering with Patient Organizations 759 
Collaboration with patient advocacy organizations can be a sound platform for successful patient 760 
engagement.   Researchers will need to familiarize themselves with the many types of organizations that 761 
vary in size and scope (e.g. rare versus high-prevalence diseases; local, regional to international).   762 
They have a range of experiences, organizational cultures, governance structures priorities, and ability 763 
and capacity to engage.  764 
 765 
Ethical Considerations 766 
Ethical issues often arise in the patient engagement process33.  Thus, following established protocols 767 
and guidelines is recommended. Rare Diseases Europe (EURORDIS) has published a Charter for 768 
Collaboration between Sponsors and Patient Organizations for Clinical Trials in Rare Diseases34.  The 769 
EXURSHDQ3DWLHQWV¶$FDGHP\EUPATI) has developed guidance for stakeholders as well35.   770 
 771 
A research contract between patients and research partners is also recommended, even if patients are 772 
driving the research themselves. The contract should be respectful and clearly outline roles and 773 
deliverables. The contract should recognize patients as experts in their health condition and compensate 774 
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them appropriately. Further information on written agreements and compensation are available from 775 
EUPATI36, PCORI37 and the European Federation of Pharmaceutical Industries and Associations 776 
(EFPIA)38.    777 
 778 
Researchers should recognize that patients are not trained researchers.   Researchers should recognize 779 
SDWLHQWV¶LQSXWLQIUDPLQJUHVHDUFKTXHVWLRQV and selecting correct methods for study conduct versus 780 
driving the research methodological or analytical approach.  However, pDWLHQWV¶RSLQLRQVshould be 781 
included throughout in the research lifecycle.   782 
 783 
Therefore,  784 
 785 
- Stakeholder input, including patients (and representatives of patients such as family caregivers and 786 
advocacy organizations) in study development, can strengthen the study design and utility: 787 
 788 
- Patient input is valuable throughout the research lifecycle from early development to 789 
dissemination and post-marketing surveillance. 790 
 791 
- Researchers should involve patients and their representatives as partners before, during, and 792 
after conducting research. 793 
 794 
- To prevent or address ethical issues arising in the patient engagement process, following established 795 
protocols and guidelines is recommended. 796 
CHAPTER 8:  PUBLICATION AND DISSEMINATION  797 
 798 
The main purpose of publishing, or otherwise disseminating HEOR, is to provide reliable and relevant 799 
information related to health care treatments and programs. Therefore, it is important that members 800 
submitting manuscripts ensure that these contain no inaccuracies, nor misrepresent the data. 801 
Publications can discuss methodological principles, the results of empirical studies, or policy choices. 802 
The main users of HEOR include decision makers concerned with population-based choices, health 803 
professionals deciding on treatment options, and patients wishing to understand more about the 804 
treatments available.  805 
 806 
Scientific Misconduct:  Plagiarism 807 
Plagiarism - WKHDFWRISDVVLQJRIIDVRQH¶VRZQDQ\ZULWLQJYHUEDWLPRUSDUDSKUDVHGWKDWwhich was 808 
authored by another - is perhaps the most fundamental ethics violation for any author in any field of 809 
endeavor.  Copyright laws protect writers' words as their legal property. Furthermore, it is extremely 810 
important to give comprehensive citations in order to avoid unintentional plagiarism.   811 
 812 
In the health and medical sciences, including HEOR, there is a gray area as to what constitutes 813 
plagiarism in the context of an individual author publishing new work that is similar in many respects to 814 
prior work on which he or she was one of several authors.  On occasion, an author is invited to submit a 815 
special article or book chapter due to prior participation in an area of important research with the 816 
expectation that their contribution will derive from the prior work.  In these instances, it is important that 817 
the author double-check to make sure that no written material (or tables or figures) is being replicated 818 
from the earlier work without permission from the copyright holder.  819 
 820 
ISPOR Code of Ethics 2017 
Final Draft for Review Only 
 
 
19 
 
In addition, ISPOR initiated a scientific and health policy group publication rule that ³No member of an 821 
ISPOR Task Force or Special Interest Group should publish any material from an upcoming report, 822 
public presentation, or project deliverable without first consulting the larger group for permission prior to 823 
submission and publication." 824 
 825 
Therefore: 826 
 827 
- Members should not engage in any act of plagiarism, including self-plagiarism.  828 
- Members should not publish any material relating to the activities of an ISPOR Task Force, 829 
Special Interest Group or other ISPOR group at any stage, without first consulting fellow group 830 
members / co-authors for permission. 831 
 832 
See chapter 5 for more on scientific misconduct.   833 
 834 
Bias 835 
A key concern in publication and dissemination is the possibility of bias, either publication bias, whereby 836 
studies with negative or inconclusive results tend not to be published, or analytic bias, whereby analysts 837 
make inappropriate methodological choices that favor one treatment option over another.  Bias is a 838 
particularly pertinent concern in the field of HEOR, where a high proportion of studies are sponsored and 839 
where the analyst often has considerable discretion in the choice of methods and assumptions. 840 
 841 
ISPOR has published more than 50 Good Practices for Outcomes Research Reports on conducting 842 
outcomes research (clinical, economic or patient-reported) or using outcomes research in health care 843 
decisions. (Please see ISPOR Good Practices for Outcomes Research Index, 844 
https://www.ispor.org/workpaper/practices_index.asp) While these reports do not address ethical 845 
principles directly, the specification of good research methods is an important component of recognizing 846 
and eliminating analytic bias. 847 
 848 
The main method of disseminating HEOR is through peer-reviewed journals. Therefore, a major source 849 
of ethical principles and good publishing practice is the recommendations of the ICMJE39, which have 850 
the endorsement and support of all the major clinical and health services research journals (ICMJE, 851 
2016). The recommendations for ISPOR members in this chapter are consistent with those of the ICMJE 852 
but offer more details relevant to this particular field of research. 853 
 854 
Freedom to Publish the Findings without Restrictions 855 
Both peer-reviewed journals and the users of HEOR take an interest in the nature of the relationship 856 
between the researcher and the sponsor, as this is one indicator of the likelihood of any bias in the 857 
research. This relationship is usually expressed through a contract between the researcher and sponsor. 858 
In negotiating the contract, researchers should pay particular attention to the need for transparency 859 
throughout the research process and the freedom to publish the findings without restrictions40.   860 
 861 
Members should seek to establish, in advance, a clear agreement with the sponsor on whether the 862 
results of a given piece of work can be published or presented. This could include statements on 863 
whether the sponsor has a right to review or approve any manuscript prior to publication and on which 864 
party has the intellectual property rights in the outputs of the research. It is important to specify 865 
publication rights, one way or the other, in the contract.  University contracts usually do specify and 866 
generally a university will not sign off on a contract that allows the sponsor to disallow publication.   Prior 867 
review and comment is generally accepted by universities.  Individual researchers or vendors may be 868 
ZLOOLQJWRGR³ZRUNIRUKLUH´ZKLFKGRHVQRWJXDUDQWHHSXEOLFDWLRQULJKWVLQVXFKDFDVHLIDQ\WKLQJLV869 
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published, it should be disclosed that publication rights were not guaranteed in advance.  Considerations 870 
where preventing publication would not be acceptable in any case could include revelations of safety 871 
issues, in which failure to disclose could result in a public health hazard. 872 
 873 
Therefore:  874 
 875 
- In the case of sponsored research, members should agree to a contract that clearly sets out their 876 
rights, and those of the sponsor (e.g., intellectual property rights and rights to publish), in the conduct 877 
and reporting of the study. The nature of this agreement should be summarized in the published paper. 878 
 879 
Transparency in Reporting  880 
Transparency in reporting is also essential to reduce the possibility of bias in research. Several reporting 881 
guidelines exist, including those developed by CONSORT for clinical research (including quality of life 882 
measurement)41 42 43 44 and STROBE for observational studies45. High-quality reporting also aids the 883 
peer-review process, although journal editors and reviewers may also ask for access to the original data, 884 
the statistical analyses performed, or the models used in the research.  885 
 886 
Authors of publications should endeavor to respond as fully as possible to requests for additional 887 
information on their data or methods. Offering full access to data, analyses and models represents a 888 
level of transparency that can enhance the credibility of the research. However, access to some data 889 
may be restricted by contractual obligations, proprietary reasons, IRB restrictions or the general need to 890 
protect the privacy of participants in the research.  Also allowing access to executable electronic copies 891 
of models has raised specific concerns on the part of researchers who fear that their intellectual capital 892 
could be undermined if the model were copied46. 893 
 894 
On the other hand, peer reviewers and journal editors may feel that access is required in order to 895 
adequately verify the quality of the research. Researchers should remember that peer reviewers are 896 
already bound by confidentiality agreements, and some journals have strengthened these in order to 897 
reassure authors that the intellectual capital in their work will be protected.  898 
 899 
It was mentioned in Chapter 4 that the registration of the clinical study alongside which a HEOR is 900 
conducted can be a key element in ensuring the transparency of research, therefore:  901 
 902 
- Where a HEOR study is being conducted alongside a clinical study gathering data prospectively (such 903 
as a clinical trial or observational study) members should report whether the clinical study concerned 904 
has been registered on ClinicalTrials.gov, Registry of Patient Registries (patientregistry.ahrq.gov), 905 
ENCePP e-Register of Studies47, or equivalent databases of studies in their own country or region. 906 
 907 
Where research is disseminated in non-peer-reviewed journals or through electronic media, such as 908 
websites or social media, the scrutiny of peer review does not generally exist (although comments 909 
sections on web posts might be considered an informal peer review). The way in which researchers 910 
should approach this depends on whether they are purporting to report fact or opinion²unless it is clear 911 
that mere opinions are being expressed, authors should be willing to offer the same level of access to 912 
underlying data and/or analyses as they would to journal peer reviewers.  913 
 914 
Study Authorship 915 
The named authors formally take responsibility for the report of the research. Therefore, some study 916 
users view the identity of the authors as one indicator of the likely quality and reliability of the research, 917 
although when acting as editors or reviewers of papers for journals, ISPOR members should make 918 
ISPOR Code of Ethics 2017 
Final Draft for Review Only 
 
 
21 
 
judgments based solely on the quality of the research, not the identity or affiliations of the authors (if 919 
these are not already anonymized by the journal concerned) 920 
 921 
Authorship also provides recognition of the UHVHDUFKHUV¶contribution. Therefore, it is wrong to include an 922 
author who did not make a substantive contribution due to their name recognition and perceived status. 923 
Similarly, it is wrong to exclude an individual who had made a substantial contribution because of their 924 
affiliation. Criteria include: 925 
 926 
1) Substantial contributions to the conception or design of the work; or the acquisition, analysis or 927 
interpretation of data for the work; AND 928 
2) Drafting of the work or revising it critically for important intellectual content; AND 929 
3) Final approval of the version to be published; AND 930 
4) Agreement to be accountable for all aspects of the work in ensuring that questions related to the 931 
accuracy or integrity of any part of the work are appropriately investigated and resolved48 932 
 933 
 934 
Other individuals participating in the research, but not qualifying as authors, should be acknowledged. 935 
 936 
In addition, the ICMJE and many peer-reviewed journals require the corresponding author to confirm 937 
that these conditions have been met. Specific journals such as JAMA have guidelines, and these are 938 
very useful generally.   939 
 940 
Journals now generally require individual authors of a manuscript to certify by signature that they have 941 
contributed sufficiently to be listed as an author.  However, journals vary in their requirements for 942 
certification so ISPOR, as an organization, encourages its members to adhere to fair and equitable 943 
requirements for authorship and to respect their colleagues in the process. 944 
 945 
Financial Disclosure, Conflicts of Interest and Past Work Relationships 946 
Another important condition of authorship is that individuals disclose any financial and/or other 947 
relationships that may be perceived to be conflicts of interest with respect to the work being reported. In 948 
the field of HEOR, it is particularly important to disclose any present or past relationships with the 949 
manufacturers of any products referred to in the research or any competitor products.  950 
 951 
In reporting past relationships, many researchers will have a large number of such relationships 952 
stretching back over a number of years. A common time frame is to report any relationships within the 953 
past three years49 , but different journals have different guidelines.  The ICMJE specifies no limit. 954 
 955 
Therefore: 956 
 957 
- Members should endeavor to publicly disseminate their work and to publish it in peer-reviewed journals 958 
when possible. 959 
 960 
- Members should work, where appropriate, to encourage the establishment and/or maintenance of an 961 
appropriate peer review process that examines the quality of the methodological rigor independently of 962 
the organization for which the individual works. 963 
 964 
- Members serving as peer reviewers for journals should respect the confidentiality of the material under 965 
review and understand that their access to it is solely for the purposes of performing the review. 966 
 967 
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- The description of study methods (design, study setting, data sources and input values, sampling and 968 
analyses) should be complete and transparent enough for a suitably trained researcher to replicate the 969 
study. 970 
 971 
- Methods sections of papers should give thorough, transparent attention to all measures taken to 972 
minimize bias. 973 
 974 
- Where allowable by law and IRB approval, members should respond favorably to requests from journal 975 
editors and reviewers for access to original data and electronic copies of models where this access is 976 
required to ensure a rigorous peer review process and where commercial-in-confidence arrangements 977 
can be maintained. 978 
 979 
- In those instances in which study methods include analysis of a database (retrospective or 980 
prospective), members should describe approaches, methods, technologies used to ensure data 981 
completeness, and validity as well as the software package(s) used for data analysis. Members should 982 
have the education, training, and experience to perform the assigned tasks. 983 
 984 
- In those instances in which sharing of model(s) and/or data source(s) is not feasible, members should 985 
be encouraged to provide supporting material demonstrating model and/or data validity, such as range 986 
and logic checks, and assessment of data completeness.    987 
 988 
- If submitting to a journal or publication that does not have peer review, or disseminating a report via 989 
electronic media, members should avoid the inclusion of material that is overly technical and/or cannot 990 
be supported by basic article references, or make it clear that the article represents the DXWKRU¶VRZQ991 
opinion.  If research is being reported, then access to the underlying data and/or analyses should be 992 
offered in the same manner as would be done under a peer-review process. 993 
 994 
- 0HPEHUVVKRXOGQHYHULQWHQWLRQDOO\SODJLDUL]HDQRWKHUDXWKRU¶VZRUNDQGLISXEOLVKLQJZRUNVLPLODUWR995 
anything jointly authored with others should ensure that no replication of the prior work was 996 
unintentionally done. 997 
CHAPTER 9: CONCLUSION AND LIMITATIONS 998 
 999 
ISPOR recognizes that within the fast changing climates of different health care systems, it is difficult to 1000 
address all ethical issues HEOR practitioners face. New data sources might emerge; genomic 1001 
sequencing and Internet of Things might make privacy almost impossible to protect; and open data 1002 
might pose new challenges to intellectual property rights. 1003 
 1004 
Nevertheless, ISPOR recognizes that its activities and those of its members affect a number of 1005 
constituencies, and there may be conflicting standards of professional conduct. Patients as stakeholders 1006 
and patient engagement are two relatively new concepts impacting health care research, especially in 1007 
Europe and North America. While the impact of this much needed social movement is slowly starting to 1008 
become clearer, its relevance and impact on ISPOR members, especially researchers, requires further 1009 
elucidation and guidance. This Code, however, cuts across virtually all areas of research and 1010 
dissemination and is meant to be a comprehensive guide for HEOR researchers. 1011 
 1012 
 1013 
 1014 
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 1016 
ISPOR CODE OF ETHICS 2017 SUMMARY POINTS 1017 
 1018 
CHAPTER 1:  INTRODUCTION 1019 
 1020 
1. ISPOR should publicize this Code of Ethics to members and non-members involved in 1021 
pharmacoeconomics and outcomes research.  1022 
2. ISPOR should strive for a balance in sponsorship of its conferences and other activities 1023 
by providing decision criteria for accepting of funding and ensuring full transparency, 1024 
thereby avoiding the appearance of bias or conflict of interest.  1025 
3. Because, as a practical matter, most funding will come from different entities, ISPOR 1026 
should continue to maintain its own statement of objectivity and autonomy.  1027 
4. ISPOR should strive to assure that its journal, Value in Health, only publishes papers 1028 
that have gone through a rigorous peer- review process.  1029 
5. ISPOR should have a Board of Directors that is representative of the various 1030 
constituencies the Society serves. 1031 
6. The ISPOR program planning and selection committees should have membership 1032 
representative of all of its major constituencies.  1033 
7. Like other professional societies, ISPOR should be conscious of broader ethical issues 1034 
impacting on global and regional medical resource allocation, public health policies and 1035 
the global healthcare environment, and the research side on topics such as patient 1036 
autonomy and research conduct. These issues include but are not limited to: prejudice, 1037 
equity in healthcare delivery and access.  1038 
 1039 
CHAPTER 2:  APPLICATION OF ETHICAL PRINCIPLES TO THE ISPOR CODE     1040 
 1041 
8. Members should maintain a current knowledge of research practices, with due 1042 
consideration of those practices most relevant to the research that is being done in their 1043 
own countries. 1044 
9. Privacy: Members who work in HEOR can be privy to data sources containing protected 1045 
health information (PHI) and other personal data from patients.  It is essential that these 1046 
data are handled with utmost care so that patient confidentiality can be maintained at all 1047 
times and no breaches to patient privacy occur.  1048 
10. Transparency and Integrity: Members must disclose research methods in sufficient detail 1049 
to permit replication. The funding sources should be clearly acknowledged, and any 1050 
conflicts of interests declared.  Designing, conducting and especially reporting of the 1051 
study should be an unbiased reflection of the full range of findings generated.  1052 
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11. &LYLOLW\0HPEHUV¶UHVHDUFKDQGGLVFXVVLRQVKRXOGUHVSHFWWKHGLJQLW\RIDOOSDUWLFLSDQWV1053 
including patients and providers of care.  It is also a responsibility to treat fellow 1054 
researchers with respect.   1055 
 1056 
CHAPTER 3:  SCOPE OF THE CODE 1057 
 1058 
12. Members should adhere to the standards of practice for their respective fields of 1059 
research and identify any official guidelines and standards used.  1060 
 1061 
CHAPTER 4:  RESEARCH DESIGN CONSIDERATIONS 1062 
 1063 
13. :KHQUHFUXLWLQJSDWLHQWVIRUDVWXG\IURPWKHSRLQWRI³ILUVW FRQWDFW´UHVHDUFKHUVVKRXOG1064 
be open about their intentions and how the research is funded, and should provide 1065 
potential subjects with the information mandated in their proposals as reviewed by 1066 
research ethics committees. 1067 
14. Members should describe the analytic population in terms of persons, geography, time 1068 
period and selection criteria.  Members should choose, and obtain permissions to use a 1069 
suitable research setting and/or existing data or literature to provide information about a 1070 
specific patient population to which the study results are meant to apply.  The number of 1071 
sites selected for a study should be appropriate to meet the research objectives.  1072 
15. Safety and adverse events reporting (AER) are important aspects of all primary research 1073 
involving patients and medical interventions, are applicable to many HEOR activities, 1074 
and must follow international guidelines.  1075 
16. The balance of risk or harm to benefit for patients must be considered in HEOR studies, 1076 
and must be communicated to patients via informed consent.  1077 
17. :KLOHDQµLQFHQWLYH¶KRQRUDULXPRUUHPXQHUDWLRQLVRIWHQQHFHVVDU\WRUHFUXLWSDUWLFLSDQWV1078 
into a research study, researchers must ensure that the incentive would not induce 1079 
participants to accept risks they would not be willing to accept if they were offered a 1080 
VPDOOHURUQRLQFHQWLYH$Q\VXFKSURSRVHGSD\PHQWVDUHVXEMHFWWRSURYLGHUV¶LQWHUQDO1081 
compliance guideline and IRB/EC approval, and must be detailed in the research 1082 
proposal submitted for review.  1083 
18. When using secondary data sources initially collected for another purpose, HEOR 1084 
researchers should ensure that intellectual property rights are respected and that all the 1085 
appropriate permissions have been secured. 1086 
19. Given the potential for bias in the analysis of secondary data, the most important general 1087 
etKLFDOSULQFLSOHVDUHWKRVHRIµUHDVRQDEOHQHVV¶DQGµWUDQVSDUHQF\¶ 1088 
20. While registration of observational studies is generally not required at this time, members 1089 
are encouraged to register such studies prospectively to recognize ethical obligations to 1090 
patients and to avoid the potential for publication bias. 1091 
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21. When study methods include analysis of a database, members should describe 1092 
approaches, methods, technologies used to ensure data completeness and validity as 1093 
well as the software package(s) used for data analysis. Members should have the 1094 
education, training and experience to perform the assigned tasks.  1095 
22. Where a HEOR study is being conducted alongside a clinical study gathering data 1096 
prospectively (such as a clinical trial or observational study),where possible members 1097 
should ensure that the clinical study concerned has been registered on 1098 
ClinicalTrials.gov, Registry of Patient Registries (patientregistry.ahrq.gov), ENCePP 1099 
(European Network of Centres for Pharmacoepidemiology and Pharmacovigilance) e-1100 
Register of Studies, or equivalent database in their own country. 1101 
23. In conducting modeling studies, members should: ensure that the input parameters are 1102 
estimated based on a comprehensive review of the available literature; be transparent 1103 
about the estimates they use for key parameters; provide the logic they used in selecting 1104 
particular estimates; and explore the impact of their choices through sensitivity analysis.  1105 
 1106 
CHAPTER 5:  DATA CONSIDERATIONS  1107 
 1108 
24. When a database (from primary data collection and/or secondary data use) is analyzed, 1109 
members should provide a description of approaches, tools and technologies used to 1110 
store the data and maintain patient privacy/confidentiality and de-identification. 1111 
25. Personal data should be maintained securely and adequate back-up should be 1112 
maintained. Data access should be limited to authorized individuals. Control systems 1113 
should be put in place to ensure authenticity, integrity and confidentiality of data records 1114 
when transmitted electronically. 1115 
26. Researchers should offer the maximum level of access to the anonymized, group-level 1116 
data used in their research.  If data access is restricted by proprietary or contractual 1117 
considerations, those considerations should be disclosed. If journal reviewers deem it 1118 
important that statistical review of proprietary data be conducted, authors should work 1119 
with both the data owners and the reviewers to find appropriate confidential 1120 
arrangements for such review whenever feasible. 1121 
27. 0HPEHUV¶K\SRWKHVHVDQGUHVHDUFKGHVLJQVVKRXOGEHGHILQHGDSULRULUHSRUWHG1122 
transparently, defended relative to alternatives, and planned to recognize and minimize 1123 
all types of bias. 1124 
28. Members should fully disclose the identity of sponsors of their research. 1125 
29. Members should strive to avoid bias and the appearance of bias in conducting research, 1126 
such as in the choice of methods and data inputs, or in the selective reporting of results 1127 
30. Members should be aware of conflicts of interest and the appearance of conflicts of 1128 
                                                        Ș encepp.eu/encepp/studiesDatabase.jsp 
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interest. As a point of reference, members should look to the rules on disclosure of 1129 
potential conflicts of interest laid down by major peer-reviewed journals and their own 1130 
institutions. 1131 
31. Members should maintain their professional autonomy and objectivity in conducting and 1132 
reporting, in writing or verbally, research findings. 1133 
32. Methods sections of papers should identify and justify all departures from the a priori 1134 
analysis plan. 1135 
33. Members should maintain and protect the integrity of data used in their studies as well 1136 
as on any other aspect of their research, as previously discussed (e.g. respect for 1137 
patient autonomy such as informed consent and data privacy). 1138 
34. Members should not draw conclusions beyond or inconsistent with what their data would 1139 
support and discuss any limitations in a transparent manner. 1140 
 1141 
CHAPTER 6:  SPONSORSHIP AND RELATIONSHIPS WITH OTHERS 1142 
 1143 
35. Members should respect the reputations and rights of colleagues when engaged in 1144 
collaborative projects 1145 
36. Members should treat their research employees with respect and should compensate 1146 
them fairly for their work. 1147 
37. Members should protect and promote the interests of their employers, provide competent 1148 
work, adhering to these broader guidelines, and protect proprietary information. 1149 
38. Members should treat students with respect and refrain from exploiting them under any 1150 
circumstances. 1151 
39. Members acting as sponsors should allow HEOR researchers at all times to maintain 1152 
their scientific integrity and adhere to relevant standards in conducting and reporting 1153 
research. 1154 
40. Members should respect contractual rights when they agree to perform work for hire and 1155 
should refrain from disseminating information which they agreed in advance to keep 1156 
proprietary. 1157 
41. When acting as key opinion leaders (KOLs), ISPOR members should be transparent 1158 
about payments ± and any other benefits - they receive for acting in this capacity.  1159 
42. When acting as KOLs, ISPOR members should ensure that the information they are 1160 
presenting is an accurate representation of the facts available. They should respond to 1161 
questions and queries honestly and to the best of their abilities.  1162 
43. When relying on KOLs, ISPOR members should critically engage with the claims being 1163 
made. Where appropriate they should seek independent corroboration of any factual 1164 
claims and consider the full range of alternatives for themselves.  1165 
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44. When acting as Advisory Board Members, ISPOR members should maintain their 1166 
independence and professional autonomy and act transparently, e.g., declare conflicts of 1167 
interest. 1168 
45. Members should respect the autonomy of research participants in designing and 1169 
conducting studies, specifically but not limited to informed consent and data privacy. 1170 
 1171 
CHAPTER 7:  PATIENT ENGAGEMENT 1172 
 1173 
46. Stakeholder input including patients (and representatives of patients such as family 1174 
caregivers and advocacy organizations) in study development, can strengthen the study 1175 
design and utility. 1176 
 1177 
a. Patient input is valuable throughout the medical product lifecycle from early 1178 
development to dissemination and post-marketing surveillance. 1179 
 1180 
b. Researchers should involve patients and their representatives as partners before, 1181 
during, and after conducting research. 1182 
 1183 
47. To prevent or address ethical issues arising in the patient engagement process, following 1184 
established protocols and guidelines is recommended. 1185 
 1186 
CHAPTER 8:  PUBLICATION AND DISSEMINATION 1187 
 1188 
48. Members should not engage in any act of plagiarism. Members should not publish any 1189 
material relating to the activities of an ISPOR Task Force, Special interest Group or other 1190 
ISPOR group without first consulting fellow group members  for permission 1191 
49. In the case of sponsored research, members should agree to a contract that clearly sets 1192 
out their rights, and those of the sponsor (e.g. intellectual property rights and rights to 1193 
publish), in the conduct and reporting of the study. The nature of this agreement should 1194 
be summarized in the published paper. 1195 
50. Where a HEOR study is being conducted alongside a clinical study gathering data 1196 
prospectively (such as a clinical trial or observational study), members should report 1197 
whether the clinical study concerned has been registered on ClinicalTrials.gov, Registry 1198 
of Patient Registries (patientregistry.ahrq.gov), ENCePP e-Register of Studies, or 1199 
equivalent database in their own country.  1200 
51. Members should endeavor to publicly disseminate their work and to publish it in peer-1201 
reviewed journals when possible.  1202 
52. Members should work, where appropriate, to encourage the establishment and/or 1203 
maintenance of an appropriate peer review process that examines the quality of the 1204 
methodological rigor independently of the organization for which the individual works. 1205 
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53. Members serving as peer reviewers for journals should respect the confidentiality of the 1206 
material under review and understand that their access to it is solely for the purposes of 1207 
performing the review. 1208 
54. The description of study methods (design, study setting, data sources and input values, 1209 
sampling and analyses) should be complete and transparent enough for a suitably 1210 
trained researcher to replicate the study. 1211 
55. Methods sections of papers should give thorough, transparent attention to all measures 1212 
taken to minimize bias. 1213 
56. Members should respond favorably to requests from journal editors and reviewers for 1214 
access to original data and electronic copies of models where this access is required to 1215 
ensure a rigorous peer review process and where commercial-in-confidence 1216 
arrangements can be maintained. 1217 
57. In those instances in which study methods include analysis of a database (retrospective 1218 
or prospective), members should describe approaches, methods, technologies used to 1219 
ensure data completeness, and validity as well as the software package(s) used for data 1220 
analysis. Members should have the education, training and experience to perform the 1221 
assigned tasks. 1222 
58. In those instances in which sharing of model(s) and/or data source(s) is not feasible, 1223 
members should be encouraged to provide supporting material demonstrating model 1224 
and/or data validity, such as range and logic checks, and assessment of data 1225 
completeness.    1226 
59. If submitting to a journal or publication that does not have peer review, or disseminating 1227 
a report via electronic media, members should avoid the inclusion of material that is 1228 
overly technical and/or cannot be supported by basic article references, or make it clear 1229 
WKDWWKHDUWLFOHUHSUHVHQWVWKHDXWKRU¶VRZQRSLQLRQ,IUHVHDUFKLVEHLQJUeported, then 1230 
access to the underlying data and/or analyses should be offered in the same manner as 1231 
would be done under a peer-review process. 1232 
60. Members should discourage, where possible, listing of an author on any publication 1233 
where the individual has not performed substantial work. As a point of reference, 1234 
members should look to the checklists provided by major peer reviewed journals to 1235 
assist them in deciding inclusion of authors. 1236 
 1237 
61. Any contributor to a report or publication should disclose any current or past 1238 
relationships with a company or competitor of any product discussed in the work. 1239 
62. 0HPEHUVVKRXOGQHYHULQWHQWLRQDOO\SODJLDUL]HDQRWKHUDXWKRU¶VZRUNDQGLISXEOLVKLQJ1240 
work similar to anything jointly authored with others should ensure that no replication of 1241 
the prior work was unintentionally done. 1242 
CHAPTER 9:  CONCLUSIONS AND LIMITATIONS 1243 
No summary points included 1244 
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ISPOR CODE OF ETHICS 2017 GLOSSARY  1245 
 1246 
AER ± Adverse Event Reporting 1247 
AHRQ ± Agency for Healthcare Research and Quality 1248 
APPI ± The Act on the Protection of Personal Information 1249 
CMS ± Center for Medicare and Medicaid Services 1250 
CONSORT - Consolidated Standards of Reporting Trials 1251 
COPE ± Committee on Publication Ethics 1252 
CRO ± Clinical Research Organization 1253 
EC ± Ethics Committee or Research Ethics Committee 1254 
EFPIA ± European Federation of Pharmaceutical Industries and Associations 1255 
ENCePP ± European Network of Centres for Pharmacoepidemiology and Pharmacovigilance 1256 
GDPR ± General Data Protection Regulation 1257 
HEOR ± Health Economics and Outcomes Research 1258 
HIPAA ± Health Insurance Portability and Accountability Act 1259 
HTA ± Health Technology Assessment 1260 
ICH GCP ± International Conference on Harmonization Good Clinical Practice 1261 
ICJME ± International Committee of Medical Journal Editors 1262 
IoT ± Internet of Things 1263 
IRB ± Internal Review Board 1264 
KOL ± Key Opinion Leader 1265 
PHI ± Protected Health Information 1266 
REC ± Ethics Committee or Research Ethics Committee 1267 
SEER ± Surveillance, Epidemiology and End Results 1268 
SNIIRAM ± 6\VWHPH1DWLRQDOG¶,QIRUPDWLRQ,QWHU5HJLPHVGHO¶$VVXUDQFH0DODGLH 1269 
STROBE -   STrengthening the Reporting of OBservational studies in Epidemiology. 1270 
TPP ± Target Patient Profile 1271 
UK HES ± United Kingdom Hospital Episode Statistics 1272 
  1273 
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